Spotify billionaire’s body scan startup has come to America

The Spotify Model for Your Bloodstream

Daniel Ek changed how we listen to music by making it frictionless. Now, he is trying to do the same for your internal organs. His health tech venture, Neko Health, is officially crossing the Atlantic, moving from European testing grounds to the American market. It is a bold move in a country where healthcare is famously expensive and notoriously reactive.

For builders, this is not just another wellness play. It is a case study in how AI and hardware are converging to solve the problem of information asymmetry in medicine. Most of us only see a doctor when something is broken. Neko is betting that people will pay to know what is happening inside them before the symptoms arrive, using high-resolution sensors and data models to map out long-term trends.

Hardware is Still Hard

Building a music streaming app is a software challenge. Building a full-body scanning suite is a logistical nightmare. Neko Health relies on a physical booth packed with sensors that take millions of data points on skin conditions, heart health, and circulation in minutes. It is the kind of deep-tech project that most founders avoid because the margins are tighter and the regulatory hurdles are higher.

However, the shift here is the move toward preventative infrastructure. For years, Silicon Valley has focused on the easy wins—telehealth apps and prescription delivery. Neko is going for the hard win: gathering baseline data. If you have a baseline, you can see the deviation. Without it, you are just guessing. This is the foundation of what I call the Founder Perspective on health: treating the body like a codebase that needs constant monitoring and logging.

The AI Layer and the Data Moat

The real value in Neko is not the scanner itself, but the data it collects. By aggregating thousands of high-fidelity body scans, they are building a proprietary dataset that traditional hospitals simply do not have. Most medical data is fragmented across thousands of legacy systems and fax machines. Neko keeps it clean, structured, and searchable.

For the AI crowd, this is the gold mine. We are moving past the era of generic Large Language Models and into the era of domain-specific intelligence. An AI trained on a million skin lesions is more valuable than one that can write a poem about them. Ek is applying the Spotify discovery engine logic to biology. Instead of discovering a new indie band, the system is looking for a microscopic change in a mole or a slight shift in arterial stiffness.

The American Hurdle

Entering the US market is a different beast than operating in Sweden or London. The healthcare system here is a patchwork of private insurers, massive hospital networks, and a legal landscape that loves a good lawsuit. Neko’s challenge will be moving from a luxury consumer product for the worried well into something that the broader medical establishment takes seriously.

There is also the skepticism factor. We have seen plenty of high-profile failures in the blood-testing and diagnostic space. Founders in this space have to work twice as hard to prove their science is sound. Neko isn't claiming to cure cancer with a drop of blood, but they are claiming to provide better data. In the US, data is only as good as the action it prompts. If a scan shows a potential issue, where does the patient go? How does it integrate with their primary care physician? These are the friction points Ek has to solve.

What Builders Should Watch

If you are building in the AI or health space, Neko’s expansion tells you three things. First, the "prosumer" health market is exploding. People no longer trust the standard medical system to keep them optimized; they want tools to do it themselves. Second, the future is multimodal. It is not just about blood work or just about heart rate; it is about combining vision, sound, and sensors into a single profile.

Third, and perhaps most importantly, the era of pure software startups is facing a reality check. The biggest problems remaining in the world—longevity, energy, transportation—require a physical presence. Neko is a reminder that to change the world, you eventually have to build something that people can walk into.

A Skeptic’s Take on Longevity

I am generally skeptical of the billionaire-funded longevity movement. There is a lot of snake oil being sold under the guise of "biohacking." However, Neko feels different because it focuses on measurement rather than immediate intervention. It is the difference between a dashboard and a mechanic. A dashboard tells you the oil is low; it doesn't try to sell you a proprietary, life-extending oil additive.

The risk for Neko is becoming a playground for the wealthy who are obsessed with their own mortality. To truly scale and make an impact, they have to drive the cost down and the accessibility up. If this stays a $500-a-pop scan for tech executives in Manhattan and San Francisco, it is a niche business. If it becomes the standard for annual check-ups, it is a revolution.

The most valuable asset any founder has is their health. If we can apply the same rigorous data analysis to our bodies that we apply to our burn rates and churn metrics, we might actually stick around long enough to see our visions through.

Takeaway: Neko Health’s US arrival marks a shift from reactive medicine to proactive data logging. For founders, the opportunity lies in the infrastructure around this data—how we store it, secure it, and ultimately, how we act on it without drowning in the noise.

Read the original at TechCrunch Startups →